Document is current
Any future updates will be listed below
-
Authors
Dahir, Kathryn M. https://orcid.org/0000-0002-9980-9138
Seefried, Lothar
Kishnani, Priya S.
Petryk, Anna
Högler, Wolfgang
Linglart, Agnès
Martos-Moreno, Gabriel Ángel
Ozono, Keiichi
Fang, Shona
Rockman-Greenberg, Cheryl
-
Funding
Funding for this research was provided by:
Alexion Pharmaceuticals
- License Information
-
More Information
Article History
Received: 24 August 2021
Accepted: 6 June 2022
First Online: 19 July 2022
Declarations
:
: The study protocol for the Global HPP Registry received approval from the institutional review board (or local equivalent) of participating study sites. Data collection and analysis were conducted in accordance with International Conference on Harmonization Good Clinical Practice Guidelines and the Declaration of Helsinki. Prior to enrollment, all participants provided written informed consent and approved the release of data contained in the medical records.
: Not applicable.
: Anna Petryk and Shona Fang are employees of, and may own stock/options in, Alexion, AstraZeneca Rare Disease. Priya S Kishnani, Gabriel Ángel Martos-Moreno, Kathryn M Dahir, Agnès Linglart, Cheryl Rockman-Greenberg, Keiichi Ozono, Lothar Seefried, and Wolfgang Högler are consultants for, and have received research funding and honoraria from, Alexion, AstraZeneca Rare Disease.
